Skip to content

The clinical value of brain pericyte marker PDGFRß and NfL in the diagnosis and treatment of ischemic stroke

The clinical value of brain pericyte marker PDGFRß and NfL in the diagnosis and treatment of ischemic stroke

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039241
Enrollment
Unknown
Registered
2020-10-22
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Gold Standard:Computed tomography (CT), magnetic resonance imaging (MRI), ultrasound or angiography.
Index test:Electrochemiluminescence&#32
for&#32
serum&#32
PDGFRß&#32
and&#32
NfL&#32
protein&#32
in&#32
patients&#32
with&#32
stroke.

Sponsors

Shanghai Tongji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Combined with clinical symptoms, signs and head MRI, it is clearly diagnosed as acute cerebral infarction (onset time <= 14 d). Acute cerebral infarction refers to the "Chinese Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018" formulated by the Neurology Branch of the Chinese Medical Association, and there is at least one cognitive area impairment). 2. First onset; 3. Aged 18 to 80 years; 4. No prodromal symptoms were seen before the onset, and cognitive function, motor function and social adaptability were all at a normal level; 5. Able to cooperate well with physical examination and neuropsychological assessment; 6. Those who voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Various reasons (including language barrier, visual barrier, consciousness barrier, etc.) cannot complete the cognitive function evaluation. 2. A history of cognitive impairment; previous mental disorders such as anxiety, depression, and mental disorders, Hamilton Depression Rating Scale (HAMD) score >= 17 points. 4. Not cooperate with follow-up research. 5. Before the onset of the stroke, the mRS score was greater than 1. 6. Long-term drug abuse or drug dependence history.

Design outcomes

Primary

MeasureTime frame
PDGFRß;neurofilament light chain, NfL;

Countries

China

Contacts

Public ContactQuan Wenqiang

Shanghai Tongji Hospital

qwq@tongji.edu.cn+86 18516505728

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026